Safety and Immunogenicity of Personalized Genomic Vaccine and Tumor Treating Fields (TTFields) to Treat Glioblastoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03223103
Recruitment Status : Active, not recruiting
First Posted : July 19, 2017
Last Update Posted : June 1, 2018
NovoCure Ltd.
Information provided by (Responsible Party):
Adilia Hormigo, Icahn School of Medicine at Mount Sinai

No Study Results Posted on for this Study
  Recruitment Status : Active, not recruiting
  Estimated Primary Completion Date : May 22, 2019
  Estimated Study Completion Date : May 22, 2020